Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995

James R. Upp, David Olson, Graeme J. Poston, Robert W. Alexander, Courtney Townsend, James C. Thompson

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Somatostatin inhibits hormone secretion from gastrointestinal endocrine tumors. The purpose of this study was to determine whether SMS 201-995, a long-acting analog, would inhibit the growth of pancreatic adenocarcinomas. Two human pancreatic cancers grown in nude mice were studied: SKI, which has cholecystokinin receptors, and CAV, which does not. Tumors were implanted in groups of six mice each. Treatment groups received SMS 201-995 (100 μg/kg three times daily) by intraperitoneal injections and control animals received saline solution. Tumor area was measured twice weekly. After 7 weeks, the tumors and mouse pancreases were excised, weighted, and analyzed for protein and RNA and DNA content. In a second set of experiments, treatment was begun 21 days after transplantation. Mean body weights between groups were not different in any experiment. With treatment beginning on the day of transplantation, the tumor areas of SKI and CAV cancers were reduced by the third and fifth weeks of treatment, respectively. Tumor doubling times were prolonged with treatment in both SKI tumors (5 days) and CAV tumors (6 days). In the SKI treatment groups, tumor weight (52 percent), RNA content (72 percent), and DNA content (60 percent) were decreased at sacrifice compared with those of the control groups. In the CAV treatment group, the mean tumor weight (55 percent) and protein (48 percent), RNA (67 percent) and DNA contents (60 percent) were decreased compared with the CAV control group. Tumor growth of SKI and CAV cancers was also inhibited when treatment was delayed 21 days after transplantation. We conclude that these effects are not mediated by inhibition of cholecystokinin, as seen by similar inhibitory effects on both tumors. Treatment with SMS 201-995 may be an effective hormonal therapy in patients with pancreatic cancers.

Original languageEnglish (US)
Pages (from-to)29-35
Number of pages7
JournalThe American Journal of Surgery
Volume155
Issue number1
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Octreotide
Somatostatin
Adenocarcinoma
Growth
Neoplasms
Therapeutics
Transplantation
RNA
Tumor Burden
Pancreatic Neoplasms
DNA
Cholecystokinin Receptors
Gastrointestinal Hormones
Control Groups
Cholecystokinin
Intraperitoneal Injections
Nude Mice
Sodium Chloride
Pancreas
Proteins

ASJC Scopus subject areas

  • Surgery

Cite this

Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995. / Upp, James R.; Olson, David; Poston, Graeme J.; Alexander, Robert W.; Townsend, Courtney; Thompson, James C.

In: The American Journal of Surgery, Vol. 155, No. 1, 1988, p. 29-35.

Research output: Contribution to journalArticle

Upp, James R. ; Olson, David ; Poston, Graeme J. ; Alexander, Robert W. ; Townsend, Courtney ; Thompson, James C. / Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995. In: The American Journal of Surgery. 1988 ; Vol. 155, No. 1. pp. 29-35.
@article{b00259a0fd18459ca288dbd9376f8dbb,
title = "Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995",
abstract = "Somatostatin inhibits hormone secretion from gastrointestinal endocrine tumors. The purpose of this study was to determine whether SMS 201-995, a long-acting analog, would inhibit the growth of pancreatic adenocarcinomas. Two human pancreatic cancers grown in nude mice were studied: SKI, which has cholecystokinin receptors, and CAV, which does not. Tumors were implanted in groups of six mice each. Treatment groups received SMS 201-995 (100 μg/kg three times daily) by intraperitoneal injections and control animals received saline solution. Tumor area was measured twice weekly. After 7 weeks, the tumors and mouse pancreases were excised, weighted, and analyzed for protein and RNA and DNA content. In a second set of experiments, treatment was begun 21 days after transplantation. Mean body weights between groups were not different in any experiment. With treatment beginning on the day of transplantation, the tumor areas of SKI and CAV cancers were reduced by the third and fifth weeks of treatment, respectively. Tumor doubling times were prolonged with treatment in both SKI tumors (5 days) and CAV tumors (6 days). In the SKI treatment groups, tumor weight (52 percent), RNA content (72 percent), and DNA content (60 percent) were decreased at sacrifice compared with those of the control groups. In the CAV treatment group, the mean tumor weight (55 percent) and protein (48 percent), RNA (67 percent) and DNA contents (60 percent) were decreased compared with the CAV control group. Tumor growth of SKI and CAV cancers was also inhibited when treatment was delayed 21 days after transplantation. We conclude that these effects are not mediated by inhibition of cholecystokinin, as seen by similar inhibitory effects on both tumors. Treatment with SMS 201-995 may be an effective hormonal therapy in patients with pancreatic cancers.",
author = "Upp, {James R.} and David Olson and Poston, {Graeme J.} and Alexander, {Robert W.} and Courtney Townsend and Thompson, {James C.}",
year = "1988",
doi = "10.1016/S0002-9610(88)80254-X",
language = "English (US)",
volume = "155",
pages = "29--35",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995

AU - Upp, James R.

AU - Olson, David

AU - Poston, Graeme J.

AU - Alexander, Robert W.

AU - Townsend, Courtney

AU - Thompson, James C.

PY - 1988

Y1 - 1988

N2 - Somatostatin inhibits hormone secretion from gastrointestinal endocrine tumors. The purpose of this study was to determine whether SMS 201-995, a long-acting analog, would inhibit the growth of pancreatic adenocarcinomas. Two human pancreatic cancers grown in nude mice were studied: SKI, which has cholecystokinin receptors, and CAV, which does not. Tumors were implanted in groups of six mice each. Treatment groups received SMS 201-995 (100 μg/kg three times daily) by intraperitoneal injections and control animals received saline solution. Tumor area was measured twice weekly. After 7 weeks, the tumors and mouse pancreases were excised, weighted, and analyzed for protein and RNA and DNA content. In a second set of experiments, treatment was begun 21 days after transplantation. Mean body weights between groups were not different in any experiment. With treatment beginning on the day of transplantation, the tumor areas of SKI and CAV cancers were reduced by the third and fifth weeks of treatment, respectively. Tumor doubling times were prolonged with treatment in both SKI tumors (5 days) and CAV tumors (6 days). In the SKI treatment groups, tumor weight (52 percent), RNA content (72 percent), and DNA content (60 percent) were decreased at sacrifice compared with those of the control groups. In the CAV treatment group, the mean tumor weight (55 percent) and protein (48 percent), RNA (67 percent) and DNA contents (60 percent) were decreased compared with the CAV control group. Tumor growth of SKI and CAV cancers was also inhibited when treatment was delayed 21 days after transplantation. We conclude that these effects are not mediated by inhibition of cholecystokinin, as seen by similar inhibitory effects on both tumors. Treatment with SMS 201-995 may be an effective hormonal therapy in patients with pancreatic cancers.

AB - Somatostatin inhibits hormone secretion from gastrointestinal endocrine tumors. The purpose of this study was to determine whether SMS 201-995, a long-acting analog, would inhibit the growth of pancreatic adenocarcinomas. Two human pancreatic cancers grown in nude mice were studied: SKI, which has cholecystokinin receptors, and CAV, which does not. Tumors were implanted in groups of six mice each. Treatment groups received SMS 201-995 (100 μg/kg three times daily) by intraperitoneal injections and control animals received saline solution. Tumor area was measured twice weekly. After 7 weeks, the tumors and mouse pancreases were excised, weighted, and analyzed for protein and RNA and DNA content. In a second set of experiments, treatment was begun 21 days after transplantation. Mean body weights between groups were not different in any experiment. With treatment beginning on the day of transplantation, the tumor areas of SKI and CAV cancers were reduced by the third and fifth weeks of treatment, respectively. Tumor doubling times were prolonged with treatment in both SKI tumors (5 days) and CAV tumors (6 days). In the SKI treatment groups, tumor weight (52 percent), RNA content (72 percent), and DNA content (60 percent) were decreased at sacrifice compared with those of the control groups. In the CAV treatment group, the mean tumor weight (55 percent) and protein (48 percent), RNA (67 percent) and DNA contents (60 percent) were decreased compared with the CAV control group. Tumor growth of SKI and CAV cancers was also inhibited when treatment was delayed 21 days after transplantation. We conclude that these effects are not mediated by inhibition of cholecystokinin, as seen by similar inhibitory effects on both tumors. Treatment with SMS 201-995 may be an effective hormonal therapy in patients with pancreatic cancers.

UR - http://www.scopus.com/inward/record.url?scp=0023851818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023851818&partnerID=8YFLogxK

U2 - 10.1016/S0002-9610(88)80254-X

DO - 10.1016/S0002-9610(88)80254-X

M3 - Article

C2 - 2893555

AN - SCOPUS:0023851818

VL - 155

SP - 29

EP - 35

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 1

ER -